Tyler Seville

ADVI’s associate director of market access policy strategy discusses how 340B grew to $100 billion, lost its safety-net purpose, and became a compliance nightmare when the IRA arrived.

ADVI's Tyler Seville on how the IRA's drug pricing provisions are creating compliance burdens manufacturers can't meet without data they don't have.

ADVI's Tyler Seville on how 340B has become a financial liability for manufacturers while covered entities expand into wealthy suburban markets.

ADVI's Tyler Seville on how 340B grew from under $10 billion to over $100 billion annually — now larger than Medicaid and Medicare Part B.